Andere Sprachen Egetis Therapeutics AB

Aktien

A1JH3B

SE0003815604

EGTX

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:23:40 03.05.2024			% 5 Tage	% 1. Jan.
6.47 ^SEK	-7.04%		+12.52%	+15.95%

03.05.	Egetis Therapeutics AB (publ) berichtet über die Ergebnisse für das erste Quartal zum 31. März 2024	CI
22.02.	Egetis Therapeutics AB (publ) meldet Ergebnis für das vierte Quartal bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03.05.
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)	24.04.
Egetis Therapeutics' : 2023 Annual Report published	15.04.
Egetis Therapeutics’ 2023 Annual Report published	15.04.
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)	29.03.
Egetis Therapeutics - Continued progress in Q4	23.02.
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.02.
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Egetis Therapeutics : – Corporate Presentation December 2023	27.12.
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance	22.12.
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	22.12.
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today	19.12.
Egetis’ Investor Day on December 19: Agenda and Registration Details	14.12.
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA	13.12.
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	13.12.
Save the Date: Egetis to host Investor Day on December 19, 2023	01.12.
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	10.11.
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan	10.11.
Egetis Therapeutics - All eyes on eventful 2024	09.11.
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Egetis Therapeutics AB

Aktien

A1JH3B

SE0003815604

EGTX

Andere Sprachen

Filter